Navigation Links
Edison Issues Initiation on Quantum Genomics (ALQGC)
Date:11/29/2016

LONDON, November 29, 2016 /PRNewswire/ --

We are initiating coverage on Quantum Genomics, a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure with a completed and an ongoing Phase IIa study, respectively. This pathway has been implicated in patients with complicated hypertension including those who are resistant to other treatments (25%) and 52% of hypertensive African Americans. We initiate with a valuation of €172m.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168)

We value Quantum Genomics at €172m or €20.51/share based on a risk-adjusted NPV. We value the two programmes at €79m and €80m, although this represents higher revenue potential ($2.1bn vs $1.3bn peak sales) and higher development cost for hypertension. We forecast that the company will require €20m in financing before it can out-license the programmes in 2019 after completing Phase IIb studies.


Click here to view the full report.

Continue Reading
Edison Logo
Edison Logo

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: Edison is an international equity research firm with a team of over 70 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact: 

Maxim Jacobs
Edison Investment Research
+1-646-653-7027

Nathaniel Calloway
Edison Investment Research
+1-646-653-7036 healthcare@edisongroup.com

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn http://www.linkedin.com/company/edison-investment-research
Twitter  http://www.twitter.com/Edison_Inv_Res
YouTube  http://www.youtube.com/edisonitv
Google+  https://plus.google.com/105425025202328783163/posts



'/>"/>
SOURCE Edison Investment Research
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. CellHealth Institute is Named 2013 Edison Award Winner
2. Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
3. Edison expands international biotechnology presence with launch of full coverage of Athersys
4. Edison Expands its European Pharmaceutical Coverage by Initiating on MagForce
5. Edison beginnt Coverage von Magforce, einem deutschen Unternehmen für nanotechnologische Krebsbekämpfung
6. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
7. Edison Initiates Coverage on Relmada Therapeutics
8. AnthroTronix Named Edison Awards Finalist for Brain Health Assessment Tool
9. Edison Initiates Coverage on Novogen
10. Edison Initiates Coverage on PDL BioPharma
11. Industry Leading Life Science Career Fair in Edison, NJ Attracts Top Employers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2017)... , ... September 17, 2017 , ... ... the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational ... against the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials ... of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will ...
(Date:9/14/2017)... ... September 14, 2017 , ... AIM Global, the worldwide standards agency for ... won the 2017 Case Study Competition for AIDC. The award is given to ... risk” and push the adoption of automated data collection systems further. The TRACTUS ...
(Date:9/12/2017)... ... September 12, 2017 , ... PhysIQ, a Chicago-based company ... ambulatory patient monitoring and clinical trial support, earned DPharm Idol 2017 honors at ... , Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital ...
Breaking Biology Technology:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):